NO971566D0 - Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF - Google Patents

Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Info

Publication number: NO971566D0
Authority: NO; Norway
Prior art keywords: kgf; diabetes mellitus; treating diabetes; mammals; pharmaceutical compositions
Prior art date: 1994-10-13

Application number

NO971566A

Other languages

English (en)

Other versions

NO971566L (no

Inventor

Sharon Lea Aukerman

Glenn Francis Pierce

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-13

Filing date

1997-04-04

Publication date

1997-04-04

1997-04-04 Application filed by Amgen Inc filed Critical Amgen Inc

1997-04-04 Publication of NO971566D0 publication Critical patent/NO971566D0/no

1997-04-14 Publication of NO971566L publication Critical patent/NO971566L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO971566A 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF NO971566L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32334094A	1994-10-13	1994-10-13
US32347594A	1994-10-13	1994-10-13
US48782595A	1995-06-07	1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en)	1994-10-13	1995-10-12	Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number	Publication Date
NO971566D0 true NO971566D0 (no)	1997-04-04
NO971566L NO971566L (no)	1997-04-14

Family

ID=27406268

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.
NO971566A NO971566L (no)	1994-10-13	1997-04-04	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Country Status (23)

Country	Link
EP (2)	EP0785948B1 (no)
JP (2)	JP4216329B2 (no)
KR (1)	KR100278597B1 (no)
CN (1)	CN1168678A (no)
AT (2)	ATE237633T1 (no)
AU (1)	AU3707795A (no)
BG (2)	BG101392A (no)
BR (2)	BR9509329A (no)
CA (2)	CA2202075C (no)
CZ (3)	CZ98197A3 (no)
DE (2)	DE69535264T2 (no)
DK (2)	DK0785948T3 (no)
EE (2)	EE03975B1 (no)
ES (2)	ES2196082T3 (no)
FI (2)	FI971420A0 (no)
HU (2)	HUT78050A (no)
NO (2)	NO318761B1 (no)
NZ (2)	NZ505502A (no)
PL (2)	PL182888B1 (no)
PT (2)	PT804479E (no)
SI (2)	SI0804479T1 (no)
SK (2)	SK284534B6 (no)
WO (2)	WO1996011949A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2153816T3 (es)	1989-01-31	2001-03-16	Jeffrey S Rubin	Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
BR9407035A (pt)	1993-06-29	1996-03-12	Chiron Corp	Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
US7084119B2 (en)	1993-06-29	2006-08-01	Chiron Corporation	Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (es) *	1994-10-13	2004-01-16	Amgen Inc.	Metodo para purificar factores de crecimiento de queratinocitos.
US7232667B2 (en)	1995-02-14	2007-06-19	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en)	1995-02-14	2004-02-17	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
US6077692A (en)	1995-02-14	2000-06-20	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
DK0822943T3 (da) *	1995-04-27	1999-11-29	Cooperatie Cosun U A	Inulinderivater
US6743422B1 (en)	1996-10-15	2004-06-01	Amgen, Inc.	Keratinocyte growth factor-2 products
ES2218666T3 (es) *	1996-10-15	2004-11-16	Amgen Inc.,	Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
EP1473366A1 (en) *	1996-10-15	2004-11-03	Amgen Inc.	Keratinocyte growth factor-2 products
US7153943B2 (en)	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
AU751898B2 (en)	1997-07-14	2002-08-29	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
KR20010033484A (ko)	1997-12-22	2001-04-25	휴먼 게놈 사이언시즈, 인크.	각질세포 성장 인자-2 제제
US6869927B1 (en)	1997-12-22	2005-03-22	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
US6242666B1 (en)	1998-12-16	2001-06-05	The Scripps Research Institute	Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
KR100731826B1 (ko) *	1999-01-14	2007-06-22	볼더 바이오테크놀로지 인코퍼레이티드	유리 시스테인 잔기를 함유하는 단백질의 제조 방법
US6248725B1 (en)	1999-02-23	2001-06-19	Amgen, Inc.	Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
KR20030074791A (ko) *	2001-02-06	2003-09-19	메르크 파텐트 게엠베하	감소된 면역원성을 갖는 개질 각질세포성장인자(ｋｇｆ)
AU2007214362B2 (en) *	2001-08-21	2009-11-26	Novartis Vaccines And Diagnostics, Inc.	KGF polypeptide compositions
MXPA04001526A (es)	2001-08-21	2004-05-31	Chiron Corp	Composiciones de polipetidos kgf.
PL1827483T3 (pl)	2004-12-15	2014-12-31	Swedish Orphan Biovitrum Ab Publ	Formulacje terapeutyczne czynnika wzrostu keratynocytów
CN102242124B (zh) *	2010-05-10	2013-05-22	齐鲁制药有限公司	改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) *	2020-08-28	2022-09-05	한국해양과학기술원	온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) *	1987-08-10	1989-05-30	Shionogi & Co Ltd	ｒｅｇ蛋白質
US5145225A (en) *	1988-07-27	1992-09-08	Muller George M	Carpet stretcher
ES2153816T3 (es) *	1989-01-31	2001-03-16	Jeffrey S Rubin	Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JP3303211B2 (ja) *	1991-04-26	2002-07-15	武田薬品工業株式会社	ｂＦＧＦムテインおよびその製造法
UA46706C2 (uk) *	1993-03-26	2002-06-17	Амген Інк.	Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція
US5348563A (en) *	1993-06-29	1994-09-20	Honeywell Inc.	Air purifying apparatus
BR9407035A (pt) *	1993-06-29	1996-03-12	Chiron Corp	Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
GB9315501D0 (en) *	1993-07-27	1993-09-08	Ici Plc	Surfactant compositions
AU7475694A (en) *	1993-08-02	1995-02-28	Prizm Pharmaceuticals, Inc.	Monogenous preparations of cytotoxic conjugates

1995
- 1995-10-12 AT AT95934793T patent/ATE237633T1/de active
- 1995-10-12 EE EE9700081A patent/EE03975B1/xx not_active IP Right Cessation
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 JP JP51307796A patent/JP4216329B2/ja not_active Expired - Fee Related
- 1995-10-12 SI SI9530728T patent/SI0804479T1/sl unknown
- 1995-10-12 SI SI9530654T patent/SI0785948T1/xx unknown
- 1995-10-12 ES ES95934793T patent/ES2196082T3/es not_active Expired - Lifetime
- 1995-10-12 DE DE69535264T patent/DE69535264T2/de not_active Expired - Lifetime
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/cs unknown
- 1995-10-12 SK SK455-97A patent/SK284534B6/sk not_active IP Right Cessation
- 1995-10-12 AT AT95934808T patent/ATE342278T1/de active
- 1995-10-12 DE DE69530403T patent/DE69530403T2/de not_active Expired - Lifetime
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en not_active Ceased
- 1995-10-12 EP EP95934793A patent/EP0785948B1/en not_active Expired - Lifetime
- 1995-10-12 DK DK95934793T patent/DK0785948T3/da active
- 1995-10-12 EE EE9700225A patent/EE9700225A/xx unknown
- 1995-10-12 PT PT95934808T patent/PT804479E/pt unknown
- 1995-10-12 DK DK95934808T patent/DK0804479T3/da active
- 1995-10-12 HU HU9901071A patent/HUT78050A/hu unknown
- 1995-10-12 EP EP95934808A patent/EP0804479B1/en not_active Expired - Lifetime
- 1995-10-12 BR BR9509329A patent/BR9509329A/pt not_active Application Discontinuation
- 1995-10-12 PL PL95319784A patent/PL182888B1/pl not_active IP Right Cessation
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/cs not_active IP Right Cessation
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/cs not_active IP Right Cessation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/ja not_active Expired - Fee Related
- 1995-10-12 PL PL95320484A patent/PL320484A1/xx unknown
- 1995-10-12 PT PT95934793T patent/PT785948E/pt unknown
- 1995-10-12 SK SK431-97A patent/SK43197A3/sk unknown
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/ko not_active Expired - Fee Related
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
- 1995-10-12 ES ES95934808T patent/ES2273338T3/es not_active Expired - Lifetime
- 1995-10-12 HU HU9901255A patent/HU226168B1/hu not_active IP Right Cessation
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en not_active Ceased
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 BR BR9509269A patent/BR9509269A/pt not_active Application Discontinuation
- 1995-10-12 FI FI971420A patent/FI971420A0/fi unknown
- 1995-10-12 CN CN95196410A patent/CN1168678A/zh active Pending
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
1997
- 1997-04-04 NO NO19971568A patent/NO318761B1/no not_active IP Right Cessation
- 1997-04-04 NO NO971566A patent/NO971566L/no unknown
- 1997-04-07 BG BG101392A patent/BG101392A/xx unknown
- 1997-04-11 BG BG101408A patent/BG63167B1/bg unknown
- 1997-04-11 FI FI971536A patent/FI120040B/fi not_active IP Right Cessation
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK45597A3 (en)	1999-02-11
EP0785948A1 (en)	1997-07-30
AU681546B2 (en)	1997-08-28
NZ505502A (en)	2005-01-28
SK43197A3 (en)	1999-03-12
FI120040B (fi)	2009-06-15
PT804479E (pt)	2007-02-28
EP0804479A1 (en)	1997-11-05
PL319784A1 (en)	1997-08-18
CZ297329B6 (cs)	2006-11-15
DE69535264D1 (de)	2006-11-23
ES2273338T3 (es)	2007-05-01
CZ105097A3 (cs)	1998-10-14
DE69530403T2 (de)	2003-10-30
AU3707795A (en)	1996-05-06
HU226168B1 (en)	2008-05-28
BG101408A (bg)	1997-12-30
KR100278597B1 (ko)	2001-01-15
CA2201940A1 (en)	1996-04-25
NO971566L (no)	1997-04-14
WO1996011949A2 (en)	1996-04-25
ATE237633T1 (de)	2003-05-15
FI971536L (fi)	1997-06-09
DE69530403D1 (de)	2003-05-22
CA2202075C (en)	2003-12-09
FI971420A7 (fi)	1997-04-04
FI971420L (fi)	1997-04-04
EP0785948B1 (en)	2003-04-16
NO318761B1 (no)	2005-05-02
PL320484A1 (en)	1997-09-29
PL182888B1 (pl)	2002-03-29
BR9509269A (pt)	1997-12-23
PT785948E (pt)	2003-09-30
CZ98197A3 (cs)	1998-11-11
EE9700225A (et)	1998-02-16
FI971536A0 (fi)	1997-04-11
NZ335109A (en)	2000-08-25
NO971568L (no)	1997-06-12
DE69535264T2 (de)	2007-02-01
FI971420A0 (fi)	1997-04-04
BG101392A (en)	1997-10-31
CA2201940C (en)	2009-05-12
SI0785948T1 (en)	2003-08-31
CN1168678A (zh)	1997-12-24
JPH10507193A (ja)	1998-07-14
JPH10507080A (ja)	1998-07-14
NO971568D0 (no)	1997-04-04
SI0804479T1 (sl)	2006-12-31
DK0785948T3 (da)	2003-08-04
ES2196082T3 (es)	2003-12-16
AU3708395A (en)	1996-05-06
CA2202075A1 (en)	1996-04-25
EP0804479B1 (en)	2006-10-11
BG63167B1 (bg)	2001-05-31
HUT78050A (hu)	1999-07-28
WO1996011950A1 (en)	1996-04-25
JP4216329B2 (ja)	2009-01-28
ATE342278T1 (de)	2006-11-15
SK284534B6 (sk)	2005-06-02
HUT78058A (hu)	1999-07-28
WO1996011949A3 (en)	1996-12-12
DK0804479T3 (da)	2007-01-29
EE9700081A (et)	1997-10-15
BR9509329A (pt)	1997-10-14
EE03975B1 (et)	2003-02-17
JP4426646B2 (ja)	2010-03-03
CZ297328B6 (cs)	2006-11-15

Publication	Publication Date	Title
NO971566D0 (no)	1997-04-04	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
FI953180A7 (fi)	1995-12-29	Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
AU8163398A (en)	1999-01-04	Inhibitors of alpha4beta1mediated cell adhesion
DE69132048D1 (de)	2000-04-20	Verwendung von Steroiden zur Inhibierung von Angiogenesis
NO20056021L (no)	1999-03-15	Anvendelse av CS-866 til fremstilling av et medikament
FI990171L (fi)	1999-03-23	Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi
AU2209500A (en)	2000-07-12	Inhibitors of alpha4beta1 mediated cell adhesion
MD960168A (ro)	1998-04-30	Metodă şi compuşi pentru tratamentul infecţiilor virale
NO982229L (no)	1998-07-15	Svovelholdige di-tert-butylfenol-forbindelser anvendbare som anti-inflammatoriske midler
FI972929A0 (fi)	1997-07-10	Kollageeniin perustuvia menetelmiä ja koostumuksia immuunijärjestelmän välittämien sairauksien hoitamiseksi
GEP20012511B (en)	2001-08-27	Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
SE9400524D0 (sv)	1994-02-16	Energipreparat
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de)	1995-08-03	Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
AUPM836794A0 (en)	1994-10-20	Improved method and composition for the treatment of ulcers
ATE315583T1 (de)	2006-02-15	Analoge des thymosin alpha 1
UA15363A (uk)	1997-06-30	Засіб для лікуваhhя відкритих пошкоджеhь
AU3597695A (en)	1996-04-09	Improved method and composition for the treatment of ulcers
AUPN733195A0 (en)	1996-01-25	Improved method and composition for the treatment of ulcers